| Janssen-Cilag AG - Trevicta 350 mg/1.75 ml, Depot-Injektionssuspension in einer Fertigspritze |
| 66054 | | 03 | | Trevicta 350 mg/1.75 ml | | Depot-Injektionssuspension in einer Fertigspritze | | N05AX13 | | Paliperidone | | 16.11.2016 | | |
|
| Composition |
| paliperidonum 350 mg ut paliperidoni palmitas 546 mg, polysorbatum 20, macrogolum 4000, acidum citricum monohydricum, natrii dihydrogenophosphas monohydricus, natrii hydroxidum, aqua ad iniectabile q.s. ad suspensionem pro 1.75 ml corresp. natrium 7.18 mg. |
| Packungsbestandteile |
| Retardsuspension zur intramuskulären Injektion | | | | | | | | Active Agent | Dose |
|---|
| Paliperidonum | 350mg / 1.75ml |
| | BAG: Active Agent | Dose |
|---|
| Paliperidonum | 350 mg |
| | | | Inactive agents | Dose |
|---|
| Citric Acid Monohydrate | | | Macrogol | 4000 | | Sodium Dihydrogenophosphate Monohydrate | | | Sodium Hydroxide | | | Polysorbatum 20 | |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 003 | | 1205.13 | 1327.05 | B | SL | Yes |
|
